Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.

por Fosså, S. D., Droz, J. P., Stoter, G., Kaye, S. B., Vermeylen, K., Sylvester, R.
Publicado 1995

The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area

por Piketty, A-C, Fléchon, A, Laplanche, A, Nouyrigat, E, Droz, J-P, Théodore, C, Fizazi, K
Publicado 2005

Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after...

por Freyer, G, Rougier, P, Bugat, R, Droz, J-P, Marty, M, Bleiberg, H, Mignard, D, Awad, L, Herait, P, Culine, S, Trillet-Lenoir, V
Publicado 2000

A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients

por Bachelot, T, Gomez, F, Biron, P, Ray-Coquard, I, Soler-Michel, P, Philip, I, Guastalla, J P, Rebattu, P, Dumortier, A, Droz, J P, Blay, J Y
Publicado 2002

Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.

por Bakker, M., Droz, J. P., Hanauske, A. R., Verweij, J., van Oosterom, A. T., Groen, H. J., Pacciarini, M. A., Domenigoni, L., van Weissenbruch, F., Pianezzola, E., de Vries, E. G.
Publicado 1998